{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:31:19Z","timestamp":1793788279156,"version":"4.6.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T00:00:00Z","timestamp":1708128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008867","name":"Department of Education of Zhejiang Province","doi-asserted-by":"publisher","award":["Y202146045"],"award-info":[{"award-number":["Y202146045"]}],"id":[{"id":"10.13039\/501100008867","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303730"],"award-info":[{"award-number":["82303730"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation","doi-asserted-by":"publisher","award":["LQ23H310011"],"award-info":[{"award-number":["LQ23H310011"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation","doi-asserted-by":"publisher","award":["LQ23H160001"],"award-info":[{"award-number":["LQ23H160001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.biopha.2024.116306","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T07:40:50Z","timestamp":1708674050000},"page":"116306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Chidamide improves gefitinib treatment outcomes in NSCLC by attenuating recruitment and immunosuppressive function of myeloid-derived suppressor cells"],"prefix":"10.1016","volume":"173","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1435-9212","authenticated-orcid":false,"given":"Jinjin","family":"Shao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichao","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4663-3722","authenticated-orcid":false,"given":"Zeren","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0376-508X","authenticated-orcid":false,"given":"Masashi","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9355-7101","authenticated-orcid":false,"given":"Zhiqi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2024.116306_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J. Clin."},{"issue":"10","key":"10.1016\/j.biopha.2024.116306_bib2","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.biopha.2024.116306_bib3","first-page":"694","article-title":"Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?, Nature reviews","volume":"15","author":"Recondo","year":"2018","journal-title":"Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2024.116306_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/bjc.2013.721","article-title":"First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study","volume":"110","author":"Douillard","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"suppl_1","key":"10.1016\/j.biopha.2024.116306_bib5","doi-asserted-by":"crossref","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","article-title":"Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors","volume":"29","author":"Westover","year":"2018","journal-title":"Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol."},{"issue":"8","key":"10.1016\/j.biopha.2024.116306_bib6","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","article-title":"Toward personalized treatment approaches for non-small-cell lung cancer","volume":"27","author":"Wang","year":"2021","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.biopha.2024.116306_bib7","first-page":"499","article-title":"Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management, Nature reviews","volume":"19","author":"Cooper","year":"2022","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.biopha.2024.116306_bib8","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2024.116306_bib9","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12943-022-01672-z","article-title":"NK cells and solid tumors: therapeutic potential and persisting obstacles","volume":"21","author":"Tong","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2024.116306_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.canlet.2020.03.013","article-title":"Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer","volume":"479","author":"Takeyama","year":"2020","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.biopha.2024.116306_bib11","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/s41467-021-22033-2","article-title":"Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway","volume":"12","author":"Alicea-Torres","year":"2021","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.biopha.2024.116306_bib12","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"10","key":"10.1016\/j.biopha.2024.116306_bib13","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1164\/rccm.201204-0636OC","article-title":"CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer","volume":"186","author":"Feng","year":"2012","journal-title":"Am. J. Respir. Crit. care Med."},{"issue":"7","key":"10.1016\/j.biopha.2024.116306_bib14","doi-asserted-by":"crossref","first-page":"7631","DOI":"10.18632\/oncotarget.24146","article-title":"S100A9(+) MDSC and TAM-mediated EGFR-TKI resistance in lung adenocarcinoma: the role of RELB","volume":"9","author":"Feng","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.biopha.2024.116306_bib15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12943-019-1073-4","article-title":"EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression","volume":"18","author":"Peng","year":"2019","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2024.116306_bib16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12943-021-01464-x","article-title":"Epigenetic modulation of antitumor immunity for improved cancer immunotherapy","volume":"20","author":"Dai","year":"2021","journal-title":"Mol. Cancer"},{"issue":"17","key":"10.1016\/j.biopha.2024.116306_bib17","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1158\/1078-0432.CCR-17-0741","article-title":"Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma","volume":"23","author":"Orillion","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.biopha.2024.116306_bib18","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1158\/2326-6066.CIR-21-0170","article-title":"Entinostat decreases immune suppression to promote antitumor responses in a HER2+ breast tumor microenvironment","volume":"10","author":"Sidiropoulos","year":"2022","journal-title":"Cancer Immunol. Res."},{"issue":"32","key":"10.1016\/j.biopha.2024.116306_bib19","doi-asserted-by":"crossref","first-page":"11774","DOI":"10.1073\/pnas.1410626111","article-title":"Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells","volume":"111","author":"Kim","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.biopha.2024.116306_bib20","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1734268","article-title":"Valproic acid attenuates CCR2-dependent tumor infiltration of monocytic myeloid-derived suppressor cells, limiting tumor progression","volume":"9","author":"Xie","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.biopha.2024.116306_bib21","article-title":"HDAC1-3 inhibition reduces CCR2 expression and immunosuppressive function of myeloid-derived suppressor cells","author":"Xie","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.biopha.2024.116306_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.932914","article-title":"Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment","volume":"13","author":"Sun","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2024.116306_bib23","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jphs.2018.06.014","article-title":"Valproic acid attenuates immunosuppressive function of myeloid-derived suppressor cells","volume":"137","author":"Xie","year":"2018","journal-title":"J. Pharmacol. Sci."},{"issue":"10","key":"10.1016\/j.biopha.2024.116306_bib24","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1080\/15548627.2020.1851492","article-title":"PLK1 (polo like kinase 1)-dependent autophagy facilitates gefitinib-induced hepatotoxicity by degrading COX6A1 (cytochrome c oxidase subunit 6A1)","volume":"17","author":"Luo","year":"2021","journal-title":"Autophagy"},{"issue":"1","key":"10.1016\/j.biopha.2024.116306_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146968","article-title":"Gefitinib synergizes with irinotecan to suppress hepatocellular carcinoma via antagonizing Rad51-mediated DNA-repair","volume":"11","author":"Shao","year":"2016","journal-title":"PloS One"},{"issue":"7605","key":"10.1016\/j.biopha.2024.116306_bib26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.biopha.2024.116306_bib27","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","article-title":"Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study","volume":"21","author":"Sequist","year":"2020","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2024.116306_bib28","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1093\/annonc\/mdy222","article-title":"Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer","volume":"30","author":"Ricordel","year":"2019","journal-title":"Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2024.116306_bib29","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.immuni.2021.04.004","article-title":"MDSC: Markers, development, states, and unaddressed complexity","volume":"54","author":"Hegde","year":"2021","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.biopha.2024.116306_bib30","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2024.116306_bib31","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/ijc.32191","article-title":"EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: implications for combination therapies","volume":"145","author":"Jia","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2024.116306_bib32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12964-020-00589-8","article-title":"CCL2\/CCR2 signaling in cancer pathogenesis","volume":"18","author":"Hao","year":"2020","journal-title":"Cell Commun. Signal.: CCS"},{"key":"10.1016\/j.biopha.2024.116306_bib33","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3389\/fimmu.2019.00757","article-title":"Tumor-stroma-inflammation networks promote pro-metastatic chemokines and aggressiveness characteristics in triple-negative","volume":"10","author":"Liubomirski","year":"2019","journal-title":"Breast Cancer, Front. Immunol."},{"issue":"29","key":"10.1016\/j.biopha.2024.116306_bib34","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1038\/s41388-019-0840-4","article-title":"Promotion of tumor-associated macrophages infiltration by elevated neddylation pathway via NF-\u03baB-CCL2 signaling in lung cancer","volume":"38","author":"Zhou","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2024.116306_bib35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jbo.2018.01.002","article-title":"Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer","volume":"11","author":"Wang","year":"2018","journal-title":"J. Bone Oncol."},{"issue":"7355","key":"10.1016\/j.biopha.2024.116306_bib36","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature10138","article-title":"CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis","volume":"475","author":"Qian","year":"2011","journal-title":"Nature"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224001872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224001872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:24:29Z","timestamp":1793787869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224001872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":36,"alternative-id":["S0753332224001872"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116306","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chidamide improves gefitinib treatment outcomes in NSCLC by attenuating recruitment and immunosuppressive function of myeloid-derived suppressor cells","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116306","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116306"}}